Pfizer hits Novo Nordisk and Metsera with lawsuit amid bidding war
Pfizer has followed through on its threats, filing a lawsuit against both Metsera and Novo Nordisk during a M&A bidding …
Post
-
-
ESMO 2025: Sichuan-Kelun moves in breast cancer ADC space
18 October 2025 marked the presentation of the highly anticipated OptiTROP-Breast02 trial at the 2025 European Society for Medical Oncology …
-
ESMO 2025: Bayer and BI neck and neck in first line HER2+ NSCLC
On 18 October 2025 at the European Society of Medical Oncology, held in Berlin, Germany, from 17 to 21 October, …
-
IntoCell and Xcellon Biologics to advance ADC development
South Korean biotechnology company IntoCell has announced a memorandum of understanding (MoU) with US-based contract development and manufacturing organisation (CDMO) …
-
4DMT and Otsuka to advance eye disease treatment in APAC
4D Molecular Therapeutics (4DMT) has announced an exclusive licence agreement with Otsuka Pharmaceutical to develop and market 4D-150, a treatment …
-
Sensei to ditch its lead candidate and cut workforce amidst strategic review
Sensei Biotherapeutics is set to abandon its sole clinical-stage asset solnerstotug as it prepares to cut its workforce and consider …
-
A new vision for keratoconus: Epioxa redefines treatment after a decade-long wait
Epioxa by Glaukos Corp received US Food and Drug Administration (FDA) approval on 20 October as the first and only …
-
How next-gen medical textiles combine comfort, safety, and sustainability
Every year, millions of disposable gowns end up in medical waste incinerators. But a new generation of sustainable textiles is …
-
Massive sales for weight loss drugs spur Eli Lilly’s Q3
As weight loss market rival Novo Nordisk drew headlines for starting a bidding war over a potential $9bn acquisition of …
-
Debiopharm and NetTargets to identify synergistic drug combos for ADCs
Swiss-based Debiopharm has formed a research partnership with South Korea-based AI drug discovery company NetTargets for the identification and development …
-
Helex secures $3.5m to advance kidney disease therapies
Helex has raised $3.5m in an oversubscribed seed funding round spearheaded by pi Ventures to advance non-viral gene therapies for …
-
Health Canada grants NOC for AstraZeneca’s breast cancer therapy
Health Canada has issued a notice of compliance (NOC) for AstraZeneca’shuman epidermal growth factor receptor 2 (HER2)-directed antibody drug conjugate …
-
FDA looks to simplify biosimilar development with new draft guidance
The US Food and Drug Administration (FDA) has debuted new draft guidance that aims to streamline and expedite the biosimilar …
-
Magazine: Cleanroom chronicles
With tighter regulations around biopharma manufacturing and the emergence of advanced therapies, cleanroom design is being fundamentally reshaped. This month's …
-
Novo Nordisk locks horns with Pfizer in late bid for Metsera
Pfizer’s agreed takeover Metsera could be in jeopardy, after Novo Nordisk submitted a rival bid to acquire the obesity biotech. Novo …
